Back to search
IDH-mutant Grade 2 or 3 Astrocytoma
Clinical trial pipeline · Data from ClinicalTrials.gov
See which IDH-mutant Grade 2 or 3 Astrocytoma trials may be worth asking aboutClinical trial pipeline · Data from ClinicalTrials.gov
See which IDH-mutant Grade 2 or 3 Astrocytoma trials may be worth asking aboutNorth America
Europe
Asia-Pacific
Rest of World
Trials may have sites in multiple countries. Filtering shows any trial with at least one site in the selected country.
This phase I trial tests the safety, side effects, and best dose of triapine in combination with radiation therapy in treating patients with glioblastoma or ast…
The primary purpose of the Phase 1 (Dose Escalation) of this study is to identify the dose-limiting toxicities (DLTs) of Debio 0123 combined with temozolomide (…
The main goal of VIGOR is to demonstrate that vorasidenib maintenance therapy improves locally assessed progression-free survival (PFS) from enrolment compared…
This randomized phase II clinical trial studies the side effects and how well proton beam or intensity-modulated radiation therapy works in preserving brain fun…
This phase 1b trial studies the side effects and best dose of telaglenastat in combination with radiation therapy and temozolomide in treating patients with IDH…